The Medicines Company enters patent settlement over Angiomax

2 April 2015

US drugmaker The Medicines Company (Nasdaq: MDCO) says it has settled its litigation with India’s Sun Pharmaceutical Industries (BSE: 524715) and certain of its subsidiaries relating to MDCO’s US Patent Nos 7,582,727 and 7,598,343 covering the anticoagulant Angiomax (bivalirudin). The patents are listed in the Orange Book and expire on July 27, 2028.

As a result of the settlement, MDCO will permit a Sun Pharma subsidiary to market a generic bivalirudin product in the USA on June 30, 2019, or earlier in certain limited circumstances. This settlement validates MDCO’s patents while allowing a Sun Pharma subsidiary to enter the market with its generic product. The other terms of the agreement are confidential. The agreement will be submitted to the applicable governmental agencies for review.

Glenn Sblendorio, president and chief financial officer of The Medicines Company, stated: “This settlement further confirms the strength of our Angiomax patents and, we believe, is a common sense approach to resolving this litigation.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK